2023-09-11T09:00:38-05:00 2022-12-31 135565207 KPMG LLP 8350 BROAD STREET SUITE 900 MCLEAN VA 22102 990 2022-01-01 823285540 COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS US COAL 2028000220 1901 PENNSYLVANIA AVENUE NW 1003 WASHINGTON DC 200063405 NICOLE LURIE PRESIDENT 2028000220 2023-09-05 1 NICOLE LURIE 999009999 0 BRIAN KEARNS P02061479 7032868000 2023-09-01 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z NICOLE LURIE 1901 PENNSYLVANIA AVENUE NW 1003 WASHINGTON DC 200063405 5017756 0 X CEPI.NET X 2017 DC CEPI IS AN INTERNATIONAL COALITION FORMED TO ACCELERATE THE DEVELOPMENT OF (SEE SCHEDULE O) VACCINES AND OTHER BIOLOGIC COUNTERMEASURES AGAINST EPIDEMIC AND PANDEMIC THREATS SO THEY CAN BE ACCESSIBLE TO ALL PEOPLE IN NEED. 3 0 27 0 0 0 3699845 5005358 0 0 10 12398 0 0 3699855 5017756 0 0 0 0 3307994 4313740 0 0 0 391861 704016 3699855 5017756 0 0 496981 1022711 496981 1022711 0 0 X COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS US ("CEPI US") WAS ORGANIZED FOR SEVERAL PURPOSES:(1) TO EDUCATE THE AMERICAN PUBLIC ABOUT THE IMPORTANCE OF DEVELOPING VACCINES TO COMBAT FUTURE GLOBAL EPIDEMICS (SEE SCHEDULE O)AND CEPI'S GOALS OF COORDINATING THE DEVELOPMENT OF SUCH VACCINES;(2) TO COORDINATE THE EFFORTS OF CEPI'S PARTNERS THAT ARE LOCATED IN THE US, INCLUDING PRIVATE FOUNDATIONS, INDUSTRY, TRADE ASSOCIATIONS, ACADEMIC AND RESEARCH INSTITUTIONS, AND OTHER NOT-FOR-PROFITS; AND,(3) TO ADVOCATE FOR SUPPORT, INCLUDING POTENTIAL FUNDING FOR CEPI US BY THE U.S. GOVERNMENT. 0 0 4977568 IN A WORLD CHARACTERIZED BY INCREASING POPULATION DENSITY, HUMAN MOBILITY, AND ECOLOGICAL CHANGE, EMERGING INFECTIOUS DISEASES POSE A REAL AND GROWING THREAT TO GLOBAL HEALTH SECURITY. EPIDEMIC DISEASES AFFECT EVERYBODY, AND DO NOT RESPECT BORDERS. VACCINES ARE ONE OF THEMOST POWERFUL TOOLS IN THE FIGHT TO OUTSMART EPIDEMICS. CEPI US'S MISSION IS TO STIMULATE AND ACCELERATE THE DEVELOPMENT OF VACCINES AGAINST EMERGING INFECTIOUS DISEASES AND ENABLE EQUITABLE ACCESS TO THESE VACCINES FOR AFFECTED POPULATIONS DURING OUTBREAKS. CEPI IS AN INNOVATIVE GLOBAL COALITION OF PUBLIC, PRIVATE, PHILANTHROPIC, AND CIVIL SOCIETY ORGANIZATIONS WITH WHOM WE WORK IN PARTNERSHIP CLOSE COLLABORATION WITH GLOBAL PARTNERS WILL BE CRUCIAL TO THE SUCCESS OF CEPIS WORK TO DEVELOP VACCINES AGAINST EMERGING (SEE SCHEDULE O) INFECTIOUS DISEASES. THEREFORE, CEPI WILL SUPPORT COORDINATING ACTIVITIES TO IMPROVE OUR COLLECTIVE RESPONSE TO EPIDEMICS, STRENGTHENING CAPACITY IN COUNTRIES AT RISK, AND ADVANCING THE REGULATORY SCIENCE THAT GOVERNS PRODUCT DEVELOPMENT. 4977568 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 27 1 0 0 0 0 0 0 0 0 0 0 0 0 X 3 0 0 0 1 0 0 1 1 1 0 0 0 1 1 0 1 1 1 1 1 0 X NICOLE LURIE 2028000220 1901 PENNSYLVANIA AVENUE NW SUITE WASHINGTON DC 200063405 RICHARD HATCHETT DIRECTOR, CEO 2.00 40.00 X X 0 710211 0 MADS HOGHOLEN DIRCTOR FIN. & OPS., TREASURER 1.00 40.00 X X 0 169867 0 NICOLE LURIE DIRECTOR, PRESIDENT 40.00 0.00 X X 274200 0 25130 MONINA VIERNEZA SECRETARY (AS OF 12/22) 1.00 40.00 X 0 239430 0 ELIZABETH A RINALDI OFFICE COORD., SEC. (UNTIL 12/22) 40.00 0.00 X 54808 0 11206 DEBRA YESKEY REGULATORY POLICY & INTEL. LEAD 40.00 0.00 X 211481 0 47204 CHRISTOPHER T DA COSTA PROJECT LEADER, R&D 40.00 0.00 X 253200 0 45812 DANIELLE CRAIG REGULATORY AFFAIRS LEAD AMERICAS 40.00 0.00 X 229270 0 62130 TIMOTHY ENDY DISEASE X PROJECT LEADER 40.00 0.00 X 263700 0 25155 REBECCA FARKAS HEAD OF TECHNOLOGY 40.00 0.00 X 267793 0 43456 1554452 1119508 260093 17 0 1 0 0 5005358 5005358 12398 12398 5017756 0 0 12398 X 1484854 1484854 2164199 2164199 252359 252359 168521 168521 243807 243807 7160 7160 33028 33028 90000 90000 75597 75597 99123 99123 301750 301750 65709 65709 11888 11888 6511 6511 7217 7217 MEMBERSHIP DUES 3520 3520 2513 2513 5017756 4977568 40188 0 472404 938144 21023 52525 56266 24224 3554 32042 496981 1022711 496981 1022711 496981 1022711 X 0 0 496981 1022711 0 0 X 0 1 X 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 56266 24224 32042 32042 X X X 0 0 0 0 0 0 0 0 0 RICHARD HATCHETT DIRECTOR, CEO 0 502386 0 205614 0 2211 0 0 0 0 0 710211 0 0 REBECCA FARKAS HEAD OF TECHNOLOGY 267793 0 0 0 0 0 18191 0 25265 0 311249 0 0 0 NICOLE LURIE DIRECTOR, PRESIDENT 274200 0 0 0 0 0 21936 0 3194 0 299330 0 0 0 CHRISTOPHER T DA COSTA PROJECT LEADER, R&D 253200 0 0 0 0 0 42256 0 3556 0 299012 0 0 0 DANIELLE CRAIG REGULATORY AFFAIRS LEAD AMERICAS 229270 0 0 0 0 0 39546 0 22584 0 291400 0 0 0 TIMOTHY ENDY DISEASE X PROJECT LEADER 263700 0 0 0 0 0 21096 0 4059 0 288855 0 0 0 DEBRA YESKEY REGULATORY POLICY & INTEL. LEAD 211481 0 0 0 0 0 43918 0 3286 0 258685 0 0 0 MONINA VIERNEZA SECRETARY (AS OF 12/22) 0 61961 0 177270 0 199 0 0 0 0 0 239430 0 0 MADS HOGHOLEN DIRCTOR FIN. & OPS., TREASURER 0 168598 0 0 0 1269 0 0 0 0 0 169867 0 0 FORM 990, PART VI, SECTION A, LINE 4 THE ORGANIZATION AMENDED ITS BYLAWS - APPROVED BY THE BOARD OF DIRECTORS AND CEPI ON 12/16/2022. FORM 990, PART VI, SECTION A, LINE 7A COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS, THE CORPORATION'S FOUNDER, HAS THE RIGHT TO APPOINT, REMOVE AND REPLACE THE DIRECTORS OF THE CORPORATION. FORM 990, PART VI, SECTION A, LINE 7B THE ARTICLES OF INCORPORATION AND BYLAWS OF THE CORPORATION MAY BE AMENDED ONLY WITH THE WRITTEN CONSENT OF THE CORPORATION'S FOUNDER, COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS. FORM 990, PART VI, SECTION A, LINE 8B THE ORGANIZATION DID CONTEMPORANEOUSLY DOCUMENT THE MEETINGS HELD OR WRITTEN ACTIONS UNDERTAKEN DURING THE YEAR BY ITS BOARD OF DIRECTORS. THE BOARD OF DIRECTORS HAS NO COMMITTEES. FORM 990, PART VI, SECTION B, LINE 11B CEPI MANAGEMENT WORKS WITH AN OUTSIDE ACCOUNTING FIRM TO PREPARE THE FORM 990. ONCE PREPARED, OPERATIONAL LEADERSHIP REVIEWS AND APPROVES THE ENTIRE FORM 990 PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C CEPI US HAS ADOPTED THE CONFLICT OF INTEREST POLICY AND PROCEDURES OF COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS. CEPI US EMPLOYEES ARE ALSO SUBJECT TO THIS POLICY. CURRENTLY, THERE ARE REVIEWS OF COI DECLARATIONS THAT ARE CONDUCTED ON A CASE BY CASE BASIS BUT THERE IS WORK IN PROGRESS TO ESTABLISH A CENTRAL SYSTEM FOR SUBMISSION OF THE COIS FOR BOTH EMPLOYEES AND EXTERNAL PARTIES, AND FRAMEWORK FOR REVIEW AND MONITORING. FORM 990, PART VI, SECTION B, LINE 15 FOR THE TOP INDIVIDUAL OR INDIVIDUALS WITH ULTIMATE RESPONSIBILITY FOR IMPLEMENTING THE DECISIONS OF CEPI US'S BOARD OF DIRECTORS, AS WELL AS OFFICERS AND KEY EMPLOYEES OF THE ORGANIZATION, CEPI US IMPLEMENTS REVIEW AND APPROVAL OF COMPENSATION BY INDEPENDENT PERSONS USING COMPARABILITY DATA. THE APPROVING BODY MUST CONCURRENTLY DOCUMENT HOW IT REACHED ITS DECISIONS, INCLUDING THE DATA ON WHICH IT RELIED. THE APPROVAL OF COMPENSATION IS DOCUMENTED IN A COMMITTEE OF THE CEPI NORWAY BOARD. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC VIA THE ORGANIZATION'S WEBSITE. FORM 990, PART IX, LINE 11G CONSULTING: PROGRAM SERVICE EXPENSES 90,000. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 90,000. CEPI NORWAY SKOYEN ATRIUM ASKEKROKEN 11 OSLO NO 0277 981407955 INTERNATIONAL HEALTH NO FOREIGN N/A 0 CEPI UK GIBBS BLDG 215 EUSTON RD BLOOMSBURY LONDON UK NW1 2BE 999999999 INTERNATIONAL HEALTH UK FOREIGN CEPI NORWAY 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CEPI NORWAY C 5005358 FAIR MARKET VALUE